Julià Gotzens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julià Gotzens has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Antoni Noguera-Julian
Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Pediatric Infectious Diseases Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain
3 shared publications - Silvia Simó Nebot
Department of Pediatric Infectious Diseases, Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Institut de Recerca Sant Joan de Déu
3 shared publications - Anna Gamell
Hospital Sant Joan de Déu Barcelona Spain
2 shared publications - Eneritz Velasco-Arnaiz
Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Pediatric Infectious Diseases Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain
2 shared publications - Marina Pons Espinal
Department of Pediatrics, Hospital Sant Joan de Déu
2 shared publications - María Ríos
Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Pediatric Infectious Diseases Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
2 shared publications
Latest Publications
- 30 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (8) , e399-e402
BK Virus-Associated Hemorrhagic Cystitis in Nontransplanted Children With Hematological Malignancies: A Single-Center Case Series
Background: BK virus–associated hemorrhagic cystitis (BKV-HC) is well recognized after hematopoietic stem-cell transplantation but remains poorly described in nontransplanted children with hematological malignancies. Observations: We retrospectively identified 6 children with leukemia or lymphoma who developed BKV-HC over a 17-year period. Dysuria and macroscopic hematuria were the most common manifestations. One patient developed urinary obstruction and acute kidney injury. Median symptom duration was 16 days. Most patients received supportive care, and all but one recovered completely without sequelae. Conclusions: BKV-HC is an uncommon complication in nontransplanted children receiving chemotherapy for hematological malignancies. Clinical outcomes are generally favorable with conservative management.
- 30 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (8) , e399-e402
BK Virus-Associated Hemorrhagic Cystitis in Nontransplanted Children With Hematological Malignancies: A Single-Center Case Series
Background: BK virus–associated hemorrhagic cystitis (BKV-HC) is well recognized after hematopoietic stem-cell transplantation but remains poorly described in nontransplanted children with hematological malignancies. Observations: We retrospectively identified 6 children with leukemia or lymphoma who developed BKV-HC over a 17-year period. Dysuria and macroscopic hematuria were the most common manifestations. One patient developed urinary obstruction and acute kidney injury. Median symptom duration was 16 days. Most patients received supportive care, and all but one recovered completely without sequelae. Conclusions: BKV-HC is an uncommon complication in nontransplanted children receiving chemotherapy for hematological malignancies. Clinical outcomes are generally favorable with conservative management.
- 22 September 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Risk of Infective Endocarditis in Pediatric Staphylococcus aureus Bacteremia
Was not provided for this article.
- 22 September 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Risk of Infective Endocarditis in Pediatric Staphylococcus aureus Bacteremia
Was not provided for this article.
- 10 September 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (9)
Early Discontinuation of Antibiotics in Pediatric Patients with Low- and High-Risk Febrile Neutropenia: A Single-Center Experience
Background: Maintaining broad-spectrum antibiotics until resolution of fever and recovery of absolute neutrophil count (ANC) has traditionally been the standard approach for pediatric patients with cancer and for hematopoietic stem-cell transplantation (HSCT) recipients who present with febrile neutropenia (FN). Recent studies in adults support the safety of discontinuing empiric antibiotic treatment (EAT) prior to ANC recovery. However, data in children remain limited. Methods: Retrospective study that included patients under 18 years of age with cancer and/or undergoing HSCT admitted with FN between June 2022 and August 2023, in whom EAT was discontinued prior to ANC ≥500/mm3. Patients already receiving antibiotics for a documented or suspected source of bacterial infection, sepsis, or admitted to pediatric intensive care unit (PICU) were excluded. We report the characteristics and clinical outcomes (readmission, new fever onset, and new infection) within 7 days of the discontinuation of EAT, as well as the 30-day PICU admission, infection-related mortality, and all-cause mortality rates. Findings: We included 97 episodes (65 patients) of FN, 47 (48.4%) occurred in children with hematologic disease (malignant or non-malignant), including patients who had received an HSCT (n = 8) and/or a chimeric antigen receptors T-cell therapy (n = 6). Fever lasted less than 24 h in 75.3% of episodes. Median EAT duration was 3 days (interquartile range [IQR]: 3-5). Absolute neutrophil count recovery occurred at a median of 4 days (IQR 2-12) after EAT discontinuation. Fever recurred in 11 episodes (11.3%) within 7 days from EAT discontinuation. An infectious cause was identified in 3/11 episodes (mild bacterial folliculitis, probable primary Cytomegalovirus infection, and invasive fungal infection, n = 1 each). No admissions to PICU or 30-day infection-related mortality were observed. Two patients died because of non-infectious causes. Conclusion: Early EAT discontinuation before ANC recovery in selected pediatric patients with FN, including high-risk patients, may reduce hospitalization and antibiotic exposure.
- 10 September 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (9)
Early Discontinuation of Antibiotics in Pediatric Patients with Low- and High-Risk Febrile Neutropenia: A Single-Center Experience
Background: Maintaining broad-spectrum antibiotics until resolution of fever and recovery of absolute neutrophil count (ANC) has traditionally been the standard approach for pediatric patients with cancer and for hematopoietic stem-cell transplantation (HSCT) recipients who present with febrile neutropenia (FN). Recent studies in adults support the safety of discontinuing empiric antibiotic treatment (EAT) prior to ANC recovery. However, data in children remain limited. Methods: Retrospective study that included patients under 18 years of age with cancer and/or undergoing HSCT admitted with FN between June 2022 and August 2023, in whom EAT was discontinued prior to ANC ≥500/mm3. Patients already receiving antibiotics for a documented or suspected source of bacterial infection, sepsis, or admitted to pediatric intensive care unit (PICU) were excluded. We report the characteristics and clinical outcomes (readmission, new fever onset, and new infection) within 7 days of the discontinuation of EAT, as well as the 30-day PICU admission, infection-related mortality, and all-cause mortality rates. Findings: We included 97 episodes (65 patients) of FN, 47 (48.4%) occurred in children with hematologic disease (malignant or non-malignant), including patients who had received an HSCT (n = 8) and/or a chimeric antigen receptors T-cell therapy (n = 6). Fever lasted less than 24 h in 75.3% of episodes. Median EAT duration was 3 days (interquartile range [IQR]: 3-5). Absolute neutrophil count recovery occurred at a median of 4 days (IQR 2-12) after EAT discontinuation. Fever recurred in 11 episodes (11.3%) within 7 days from EAT discontinuation. An infectious cause was identified in 3/11 episodes (mild bacterial folliculitis, probable primary Cytomegalovirus infection, and invasive fungal infection, n = 1 each). No admissions to PICU or 30-day infection-related mortality were observed. Two patients died because of non-infectious causes. Conclusion: Early EAT discontinuation before ANC recovery in selected pediatric patients with FN, including high-risk patients, may reduce hospitalization and antibiotic exposure.
- Open Access
- 21 August 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (8) , 847
Blood Cultures Time-to-Positivity as an Antibiotic Stewardship Tool in Immunocompromised Children with Gram-Negative Bacteraemia
Background/Objectives: Children and adolescents with haematologic malignancies or other causes of immunosuppression are at high risk of severe infections. Determining the probability of Gram-negative bacilli bloodstream infections (GNB-BSI) within 24 h of blood culture (BC) incubation could support early antibiotic de-escalation, compared to the current guidelines recommending de-escalation after 48–72 h. Methods: Retrospective, observational single-centre study describing BC time-to-positivity (TTP) in GNB-BSI in a paediatric cohort of immunocompromised children. Results: In 128 episodes (100 patients), TTP was less than 24 h in >95% cases. TTP did not differ based on sex, underlying disease, degree of neutropenia, or PICU admission. Antibiotic initiation prior to BC collection and microbiological aetiology (microbiological aetiology different from Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae) were the only identified risk factors associated with BC growth beyond 24 h. No patients with late BC growth died or required PICU admission. Conclusions: If BC remains negative after 24 h of incubation, GNB-BSI is unlikely in immunocompromised children and adolescents with fever. These results support early de-escalation strategies, shortening unnecessary exposure to broader-spectrum antibiotics, and potentially decreasing adverse events and costs.
- 21 August 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (8) , 847
Open AccessBlood Cultures Time-to-Positivity as an Antibiotic Stewardship Tool in Immunocompromised Children with Gram-Negative Bacteraemia
Background/Objectives: Children and adolescents with haematologic malignancies or other causes of immunosuppression are at high risk of severe infections. Determining the probability of Gram-negative bacilli bloodstream infections (GNB-BSI) within 24 h of blood culture (BC) incubation could support early antibiotic de-escalation, compared to the current guidelines recommending de-escalation after 48–72 h. Methods: Retrospective, observational single-centre study describing BC time-to-positivity (TTP) in GNB-BSI in a paediatric cohort of immunocompromised children. Results: In 128 episodes (100 patients), TTP was less than 24 h in >95% cases. TTP did not differ based on sex, underlying disease, degree of neutropenia, or PICU admission. Antibiotic initiation prior to BC collection and microbiological aetiology (microbiological aetiology different from Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae) were the only identified risk factors associated with BC growth beyond 24 h. No patients with late BC growth died or required PICU admission. Conclusions: If BC remains negative after 24 h of incubation, GNB-BSI is unlikely in immunocompromised children and adolescents with fever. These results support early de-escalation strategies, shortening unnecessary exposure to broader-spectrum antibiotics, and potentially decreasing adverse events and costs.